WASHINGTON, Nov 10 (Reuters) - U.S. drug reviewers could not determine the tamper-resistance properties of an experimental painkiller developed by King Pharmaceuticals (KG.N: Quote, Profile, Research, Stock Buzz) and Pain Therapeutics (PTIE.O: Quote, Profile, Research, Stock Buzz), an analysis released on Monday said.
